- Home
- GLTO vs EBON Comparison
GLTO vs EBON Comparison
Compare GLTO & EBON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- EBON
- Stock Information
- Founded
- GLTO 2011
- EBON 2010
- Country
- GLTO Denmark
- EBON China
- Employees
- GLTO N/A
- EBON N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- EBON Semiconductors
- Sector
- GLTO Health Care
- EBON Technology
- Exchange
- GLTO Nasdaq
- EBON Nasdaq
- Market Cap
- GLTO 23.7M
- EBON 24.4M
- IPO Year
- GLTO 2020
- EBON 2020
- Fundamental
- Price
- GLTO $10.99
- EBON $4.63
- Analyst Decision
- GLTO Buy
- EBON
- Analyst Count
- GLTO 1
- EBON 0
- Target Price
- GLTO $10.00
- EBON N/A
- AVG Volume (30 Days)
- GLTO 7.6M
- EBON 22.4K
- Earning Date
- GLTO 10-31-2025
- EBON 08-15-2025
- Dividend Yield
- GLTO N/A
- EBON N/A
- EPS Growth
- GLTO N/A
- EBON N/A
- EPS
- GLTO N/A
- EBON N/A
- Revenue
- GLTO N/A
- EBON $7,337,066.00
- Revenue This Year
- GLTO N/A
- EBON N/A
- Revenue Next Year
- GLTO N/A
- EBON N/A
- P/E Ratio
- GLTO N/A
- EBON N/A
- Revenue Growth
- GLTO N/A
- EBON 104.28
- 52 Week Low
- GLTO $2.01
- EBON $3.00
- 52 Week High
- GLTO $31.70
- EBON $10.94
- Technical
- Relative Strength Index (RSI)
- GLTO 58.62
- EBON 48.73
- Support Level
- GLTO $10.53
- EBON $4.25
- Resistance Level
- GLTO $18.45
- EBON $5.90
- Average True Range (ATR)
- GLTO 2.35
- EBON 0.53
- MACD
- GLTO 0.43
- EBON -0.05
- Stochastic Oscillator
- GLTO 26.56
- EBON 23.03
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.